Plasminogen activator Inhibitor Type 1 Human Chromogenic Activity Kit (ab108894) has been developed to determine human type I plasminogen activator inhibitor (PAI-1) activity in cell culture supernatant, serum, and plasma samples.
Images
Publications
Filter by
- Molecular neurobiology 60:6441-64652023Extracellular Vesicle-Serpine-1 Affects Neural Progenitor Cell Mitochondrial Networks and Synaptic Density: Modulation by Amyloid Beta and HIV-1.Applications:Unspecified applicationReactive species:Unspecified reactive speciesIbolya E András,Nelson Serrano,Irina Djuraskovic,Nikolai Fattakhov,Enze Sun,Michal ToborekPubMed 37458985
Key facts
- Detection method
- Colorimetric
- Sample types
- Cell culture supernatant, Plasma, Serum
- Assay type
- Quantitative
- Range
- 0.625 - 20 IU/mL
- Sensitivity
- = 0.57 AU/mL
Target data
Function
Serine protease inhibitor. Inhibits TMPRSS7 (PubMed:15853774). Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots (PubMed:17912461, PubMed:8481516, PubMed:9207454). As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading (PubMed:9175705). Acts as a regulator of cell migration, independently of its role as protease inhibitor (PubMed:15001579, PubMed:9168821). It is required for stimulation of keratinocyte migration during cutaneous injury repair (PubMed:18386027). It is involved in cellular and replicative senescence (PubMed:16862142). Plays a role in alveolar type 2 cells senescence in the lung (By similarity). Is involved in the regulation of cementogenic differentiation of periodontal ligament stem cells, and regulates odontoblast differentiation and dentin formation during odontogenesis (PubMed:25808697, PubMed:27046084).
Alternative names
PAI1, PLANH1, SERPINE1, Plasminogen activator inhibitor 1, PAI, PAI-1, Endothelial plasminogen activator inhibitor, Serpin E1
What's included?
Recommended products
Plasminogen activator Inhibitor Type 1 Human Chromogenic Activity Kit (ab108894) has been developed to determine human type I plasminogen activator inhibitor (PAI-1) activity in cell culture supernatant, serum, and plasma samples.
Key facts
- Detection method
- Colorimetric
- Sample types
- Cell culture supernatant, Plasma, Serum
- Assay type
- Quantitative
- Range
- 0.625 - 20 IU/mL
- Assay Platform
- Microplate reader
- Sensitivity
- = 0.57 AU/mL
Storage
- Shipped at conditions
- Blue Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- Multi
- Storage information
- Please refer to protocols
Notes
Plasminogen activator Inhibitor Type 1 Human Chromogenic Activity Kit (ab108894) has been developed to determine human type I plasminogen activator inhibitor (PAI-1) activity in cell culture supernatant, serum, and plasma samples.
A fixed amount of tissue-type plasminogen activator (tPA) is added in excess to undiluted sample, which allows PAI-1 and tPA to form an inactive complex. The assay measures plasminogen activation by residual tPA in coupled assays that contain tPA, plasminogen, and a plasmin-specific synthetic substrate. The amount of plasmin produced is quantitated using a highly specific plasmin substrate releasing a yellow para-nitroaniline (pNA) chromophore. The absorbance of the pNA at 405 nm is inversely proportional to the PAI-1 enzymatic activity.
Upon arrival, immediately store components of the kit at recommended temperatures. Avoid repeated freeze-thaw cycles.
Type I plasminogen activator inhibitor (PAI-1) is a 50 kDa serpin family member that inhibits tissue- and urokinase-type plaminogen activators (t-PA, u-PA). This protein appears to be an important regulator of plasminogen activation by t-PA and extracellular proteolysis by u-PA. The plasminogen activator proteolytic enzyme systems are important not only for fibrinolysis but also for extracellular matrix remodeling, and have been implicated in a number of normal and pathological processes including angiogensis, ovulation and embryogenesis, thrombotic and hemorrhagic disorders, connective tissue diseases, neoplasm and sepsis. PAI-1 is a prognosticator in breast cancer, gastric cancer, various forms of lung cancer and cervical cancer.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Plasminogen Activator Inhibitor 1 (PAI-1) also known as SERPINE1 mechanically acts as an important regulator of fibrinolysis. It does this by inhibiting tissue plasminogen activator (tPA) and urokinase (uPA) which convert plasminogen to plasmin an enzyme that digests fibrin clots. PAI-1 is a single-chain glycoprotein with a molecular mass of approximately 50 kDa. It expresses in many tissues including liver adipose tissue and endothelial cells and has an important role in maintaining the balance between clot formation and dissolution.
- Biological function summary
PAI-1 has essential functions in processes beyond fibrinolysis. It participates in extracellular matrix remodeling cell migration and tissue repair. PAI-1 interacts with vitronectin in plasma forming a complex that stabilizes its inhibitory function. This interaction affects angiogenesis and wound healing by modulating cell adhesion and migration highlighting PAI-1's versatility in different biological processes.
- Pathways
PAI-1 significantly influences hemostasis and cell signaling networks. It plays a role in the plasminogen activation system a vital aspect of the hemostatic pathway which prevents excessive blood clot formation. Furthermore PAI-1 interacts with transforming growth factor-beta (TGF-β) in signaling pathways involved in cellular regulation. These interactions highlight PAI-1's link to proteins such as tPA and uPA which are critical in modulating fibrinolytic activity.
- Associated diseases and disorders
Elevated levels of PAI-1 are often associated with conditions like thrombosis and atherosclerosis. Thrombosis results from excessive fibrin formation due to insufficient plasminogen activation implicating PAI-1's inhibition in tPA and uPA activity. In cardiovascular disease contexts such as atherosclerosis PAI-1 influences the stability of atherosclerotic plaques. It also associates with diseases featuring excessive fibrosis due to PAI-1's regulatory effect on TGF-β-mediated pathways highlighting its connection to the pathological processes in both thrombosis and cardiovascular disorders.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Functional Studies - Plasminogen activator Inhibitor Type 1 Human Chromogenic Activity Assay Kit (ab108894)
Example of Standard Curve.
Representative Standard Curve using ab108894.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com